2020
379-P: Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes
KAHN P, LIU S, MCCOY R, GABBAY R, LIPSKA K. 379-P: Glucagon Use by U.S. Adults with Type 1 and Type 2 Diabetes. Diabetes 2020, 69 DOI: 10.2337/db20-379-p.Peer-Reviewed Original ResearchType 2 diabetesHigh-risk patientsType 1Diabetes patientsGlucagon useType 1 diabetes patientsAmerican Diabetes AssociationType 1 diabetesMedicare Advantage enrolleesPoor discriminative performanceGlucagon prescriptionsPrior hypoglycemiaRisk patientsDiabetes AssociationPrescribing practicesEndocrinology careMultivariable modelAdministrative claimsHigh riskPatientsType 2DiabetesModel AUCU.S. adultsGlucagon
2019
1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy. Diabetes 2019, 68 DOI: 10.2337/db19-1249-p.Peer-Reviewed Original ResearchGlucose lowering therapiesOptimal therapeutic regimensGlucose lowering medicationsDiabetes quality indicatorsNational InstituteMedicare Advantage enrolleesPatient-centered approachHigh-complexity patientsPerson/yearComorbidity burdenHospitalization visitsTreatment burdenHypoglycemia riskKidney diseaseTherapeutic regimensNational cohortNumber/typeClinical complexityPatientsMedicaid ServicesOptumLabsDiabetesTherapyVisitsAmerican Association1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1607-p.Peer-Reviewed Original ResearchType 1 diabetesClinical complexityRace/ethnicityMale sexYounger ageAsian race/ethnicityHispanic race/ethnicityGlucose-lowering medicationsPoor glycemic controlLong-term complicationsHigh clinical complexityNational InstituteMedicare Advantage enrolleesAdministrative claims datasetEndocrine managementPatient comorbiditiesGlycemic controlTreatment regimenStudy cohortKidney diseasePotential overtreatmentDiabetesFM managementOvertreatmentU.S. adults